longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Cognition Therapeutics

CGTX

0.98280.32% ( +0.0031 )
Closed: Sep 11, 16:00:01 (EDT)
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -5.55, below the reasonable range, cheaper than 93.75% of the time in the past 3 years, and the industry ranks 162/258, the industry Median -1.32.

-5.55xP/E
$0.98Stock price
$-0.18Earnings per share
-5.55xP/E
Stock price$0.98Earnings per share$-0.18

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.46x
Typical range
-4.49x–-0.76x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-54.79x14.01%$57.21B
BAYZFUSBayer Aktiengesellschaft
-27.51x--$55.50B
BAYRYUSBayer
-27.40x--$55.29B
VTRSUSViatris
-45.81x110.35%$18.81B
ELANUSElanco Animal Health
-57.39x129.36%$11.42B
VREOFUSVIREO GROWTH INC
-169.69x--$11.39B
AXSMUSAxsome Therap
-57.70x27.32%$11.06B
CURLFUSCuraleaf Holdings, Inc.
-144.62x--$7.52B
BLTEUSBelite Bio
-68.88x29.87%$7.05B
DFTXUSDefinium Therapeutics
-14.33x53.67%$5.07B
EWTXUSEdgewise Therapeutics
-23.62x137.29%$4.66B
ELVNUSEnliven Therapeutics
-38.89x1.17%$4.12B
MANEUSVeraDermics
-39.32x97.39%$4.10B
AMLXUSAmylyx Pharmaceuticals
-26.48x1.76%$4.03B
TARSUSTarsus Pharmaceuticals
-76.59x34.09%$3.56B
MBXUSMBX Biosciences
-28.14x32.19%$2.93B
GPCRUSStructure Therapeutics
-13.13x104.48%$2.82B
RGCUSRegencell Bioscience
-396.11x--$2.79B
ATAIUSAtaiBeckley
-4.08x86.86%$2.73B
PHVSUSPharvaris BV
-13.27x7.47%$2.63B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.